The Effect of Sulfasalazine on CRH Levels in Pregnant Women
ConditionPreterm Birth
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorRutgers, The State University of New Jersey
About this trial
The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are:
* Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls?
Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.
Eligibility criteria
Qualifiers
> 18 years of age
Singleton pregnancy
Participants with a history of prior preterm birth in a previous pregnancy
Participants must be between 12 and 22 weeks gestation.
Disqualifiers
Participants < 18 years old
Participants with a cervical length < 25 mm
Participants with a multiple gestation
Cerclage
Trial design
Treatments tested in this trial
- Sulfasalazine
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov